There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AstraZeneca (AZN – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report) with bullish sentiments.
AstraZeneca (AZN)
In a report released yesterday, Etzer Darout from BMO Capital maintained a Buy rating on AstraZeneca, with a price target of $80.00. The company’s shares closed last Thursday at $75.03, close to its 52-week high of $76.56.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a $80.36 average price target, a 7.2% upside from current levels. In a report issued on April 22, Morgan Stanley also maintained a Buy rating on the stock with a $84.00 price target.
See the top stocks recommended by analysts >>
BioMarin Pharmaceutical (BMRN)
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $115.00. The company’s shares closed last Thursday at $82.17.
According to TipRanks.com, Biliouris is a 1-star analyst with an average return of
BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $111.48, which is a 29.2% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Buy rating on the stock with a $140.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AZN:
- 3 Best Healthcare Stocks to Buy in April 2024, According to Analysts
- AstraZeneca’s Q1 2024: Revenue and Dividend Leap
- AstraZeneca backs FY24 core EPS view up low double-digit to low teens percentage
- AstraZeneca reports Q1 core EPS $2.06, consensus $1.22
- AZN Earnings: AstraZeneca Soars on Impressive Q1 Results
